Fig. 2

LS mean change from baseline in the number of monthly migraine headache days in patients who did not benefit from migraine preventive medication due to safety or tolerability. *p<0.05, **p<0.01 vs placebo. ^aOnly one patient discontinued onabotulinum toxin A due to safety/tolerability reasons; therefore, no statistical analyses were performed. Change from baseline showed a numerical reduction in monthly migraine headache days. Abbreviations: LS least-squares, N number of intent-to-treat patients, SE standard error